GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neurizon Therapeutics Ltd (FRA:ECQ0) » Definitions » Beta

Neurizon Therapeutics (FRA:ECQ0) Beta : 2.11 (As of Dec. 13, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Neurizon Therapeutics Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2024-12-13), Neurizon Therapeutics's Beta is 2.11.


Neurizon Therapeutics Beta Historical Data

The historical data trend for Neurizon Therapeutics's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neurizon Therapeutics Beta Chart

Neurizon Therapeutics Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.39 1.48 2.31 0.97 2.12

Neurizon Therapeutics Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.31 1.66 0.97 2.21 2.12

Competitive Comparison of Neurizon Therapeutics's Beta

For the Biotechnology subindustry, Neurizon Therapeutics's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neurizon Therapeutics's Beta Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Neurizon Therapeutics's Beta distribution charts can be found below:

* The bar in red indicates where Neurizon Therapeutics's Beta falls into.



Neurizon Therapeutics Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.


Neurizon Therapeutics  (FRA:ECQ0) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Neurizon Therapeutics Beta Related Terms

Thank you for viewing the detailed overview of Neurizon Therapeutics's Beta provided by GuruFocus.com. Please click on the following links to see related term pages.


Neurizon Therapeutics Business Description

Traded in Other Exchanges
Address
96-100 Albert Road, Level 4, South Melbourne, Melbourne, VIC, AUS, 3205
Neurizon Therapeutics Ltd is a clinical-stage biotech company that develops drug discovery intellectual property for the treatment of different types of neurodegenerative diseases. Its product pipeline is NUZ-001 (S-Monepantel).

Neurizon Therapeutics Headlines

No Headlines